Neurology

Bilateral Focused Ultrasound: A New Path for Parkinson's Motor Control?

Staged, bilateral MRgFUS pallidothalamic tractotomy significantly improved motor complications in Parkinson's disease, offering an incisionless alternative to DBS.

Dual-target gene therapy: Can it free Parkinson's patients from levodopa dependence?

A dual-target gene therapy, BBM-P002, demonstrated a favorable safety profile in a Phase 1 trial for moderate-to-advanced Parkinson's disease.

Why HINTS examination outperforms imaging for acute vertigo

The HINTS examination accurately differentiates central from peripheral vertigo, reducing unnecessary neuroimaging in emergency department patients.

Vestibular Migraine vs. Meniere Disease: Separating Overlapping Diagnoses

Differentiating vestibular migraine from Meniere disease remains a clinical challenge, but emerging biomarkers and refined diagnostic criteria offer clearer distinctions.

Do CGRP Monoclonal Antibodies Offer Relief for Vestibular Migraine Vertigo?

CGRP monoclonal antibodies, established for migraine prophylaxis, are being explored for their potential to reduce vertigo attacks in vestibular migraine, a condition often challenging to manage.

Why long COVID research still struggles with a case definition

Long COVID research faces significant hurdles due to the lack of a consistent case definition, hindering clinical trials and patient care.

Unpacking Post-COVID Dysautonomia and POTS in General Practice

Post-COVID dysautonomia, including POTS, presents a diagnostic challenge in general practice, requiring careful assessment of symptoms and exclusion of other conditions. Early recognition is key for appropriate management strategies.

Unpacking the long-term cognitive toll of COVID-19

Cognitive deficits after COVID-19 persist in many patients, with recovery patterns varying significantly across domains and over time.

Suzetrigine: A new mechanism for neuropathic pain, but what does it mean for practice?

Suzetrigine introduces a novel mechanism for neuropathic pain, targeting Nav1.8 channels. This approach offers a potential alternative to existing treatments.